Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Direxion Shares ETF Trust (CURE)

19 + Investors. Track Smart Money conviction in CURE. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +5
Streak
1Q ▲
Buyers last Q
62%

Smart Money Signals — CURE

Based on 22 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added CURE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (96% of max)

96% of all-time peak
22 hedge funds hold CURE right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📉

Outflows — 4% fewer funds vs a year ago

fund count last 6Q
1 fewer hedge funds hold CURE compared to a year ago (-4% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟢

More buyers than sellers — 62% buying

16 buying10 selling
Last quarter: 16 funds were net buyers (8 opened a brand new position + 8 added to an existing one). Only 10 were sellers (7 trimmed + 3 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new CURE position: 7 → 4 → 2 → 8. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

50% of holders stayed for 2+ years

■ 50% conviction (2yr+) ■ 27% medium ■ 23% new
11 out of 22 hedge funds have held CURE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +73% but shares only +41% — price-driven

Value
+72%
Shares
+40%
Last quarter: the total dollar value of institutional holdings rose +73%, but actual share count only changed +41%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
➡️

Steady discovery — ~8 new funds/quarter

7 → 7 → 4 → 2 → 8 new funds/Q
New funds entering each quarter: 7 → 4 → 2 → 8. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 70% veterans vs 22% newcomers

■ 70% veterans ■ 7% 1-2yr ■ 22% new
Entry-cohort mix of 27 holders: 19 (70%) are 2+ year veterans, 2 entered 1–2 years ago, and 6 (22%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 61% AUM from top-100 funds

61% from top-100 AUM funds
7 of 20 holders are among the 100 largest funds by AUM, controlling 61% of total institutional value in CURE. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.4
out of 10
Low Exit Risk
Exit risk score 3.4/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CURE

In 2026 Q2, 16 hedge funds were net buyers of CURE (8 opened a new position, 8 added to an existing one), while 10 reduced or exited (7 trimmed, 3 sold completely) — a 62% buyer ratio, indicating clear institutional accumulation. 61% of total institutional value in CURE is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +5 funds (more new holders than closures). Total institutional holders: 22.

Hedge Fund Ownership: CURE

How many hedge funds hold CURE — quarterly history vs. share price
Quarterly hedge fund ownership of CURE vs. share price

Market Analysis: CURE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CURE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Loading signal freshness…
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

0 top-rated funds 0 high-conviction
Consensus
0.0
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: CURE
2026 Q3 Stats Unlock in 44 days 19 + Investors

Track Smart Money conviction in CURE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 19 17 11.76%
13F Shares 347K 246K 40.79%
Total Value $39M $23M 72.51%
New Positions 7 2 +5
Increased Positions 7 5 +2
Closed Positions 3 5 -2
Reduced Positions 5 8 -3
Total Calls 4 4 -
Total Puts 3 3 -
PUT/CALL Ratio 0.75 0.75 Neutral

Statistics: CURE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

19 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CURE. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CURE holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Onyx Bridge Wealth Group LLC 0.03% 2,493 $280K
2 Traynor Capital Management, Inc. 0.02% 4,737 $531K
3 SBI Securities Co., Ltd. 0.01% 4,987 $559K
4 StoneX Group Inc. 0.01% 2,316 $228K
5 Larson Financial Group LLC 0.01% 2,847 $319K
6 Bullseye Investment Management, LLC 0.01% 120 $13K
7 Summit Financial, LLC 0.01% 4,105 $460K
8 Pinnacle Wealth Planning Services, Inc. 0.00% 434 $49K
9 Belvedere Trading LLC 0.00% 12,800 $1.4M
10 Citadel Advisors LLC 0.00% 56,500 $6.3M
11 Citadel Advisors LLC 0.00% 39,500 $4.4M
12 Susquehanna International Group, LLP 0.00% 55,800 $6.3M
13 Goldman Sachs Group Inc 0.00% 41,158 $4.6M
14 Farther Finance Advisors, LLC 0.00% 330 $37K
15 Susquehanna International Group, LLP 0.00% 33,000 $3.7M
16 Jane Street Group, LLC 0.00% 29,600 $3.3M
17 Jane Street Group, LLC 0.00% 25,141 $2.8M
18 Susquehanna International Group, LLP 0.00% 19,504 $2.2M
19 Qube Research & Technologies Ltd 0.00% 1,212 $136K
20 Jane Street Group, LLC 0.00% 7,900 $886K
21 Simplex Trading, LLC 0.00% 1,057 $119K
22 Osaic Holdings, INC. 0.00% 194 $22K
23 UBS Group AG 0.00% 999 $112K
24 Mercer Global Advisors Inc /Adv 0.00% 44 $5K
25 Royal Bank of Canada 0.00% 35 $4K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Direxion Shares ETF Trust (CURE)

What does the Smart Money Trend signal show for CURE?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added CURE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CURE?

More buyers than sellers — 62% buying: Last quarter: 16 funds were net buyers (8 opened a brand new position + 8 added to an existing one). Only 10 were sellers (7 trimmed + 3 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CURE holders?

Elite ownership — 61% AUM from top-100 funds: 7 of 20 holders are among the 100 largest funds by AUM, controlling 61% of total institutional value in CURE. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CURE?

50% of holders stayed for 2+ years: 11 out of 22 hedge funds have held CURE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →